U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N3O5
Molecular Weight 243.217
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYTARABINE

SMILES

c1cn([C@@]2([H])[C@]([H])([C@@]([H])([C@@]([H])(CO)O2)O)O)c(nc1=N)O

InChI

InChIKey=UHDGCWIWMRVCDJ-CCXZUQQUSA-N
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C9H13N3O5
Molecular Weight 243.217
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment:: Description was created using several sources including: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680 http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330

Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.

CNS Activity

Originator

Curator's Comment:: Cytarabine was first synthesized in 1959 by Richard Walwick, Walden Roberts, and Charles Dekker at the University of California, Berkeley. It was approved by the United States Food and Drug Administration in June 1969, and was initially marketed in the U.S. by Upjohn under the trade name Cytosar-U and is at present manufactured by Pfizer, Sicor Pharmaceuticals and Teva. CYTOSAR (cytarabine injection) was developed in September 1994 Dana-­Farber Cancer Institute and is manufactured by Pfizer and Perrigo. DEPOCYT - (cytarabine injection, lipid complex) manufactured by Manufactured by: Pacira Pharmaceuticals Inc., distributed by Sigma-Tau Pharmaceutical, Inc. is an intrathecal cancer chemotherapeutic agent approved by FDA is used for the treatment of lymphomatous meningitis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Primary
CYTARABINE

Approved Use

Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.

Launch Date

-1.71072E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.2 μg/mL
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1900 μg × h/mL
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40.4 h
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80 h
50 mg single, intrathecal
dose: 50 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
CYTARABINE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Disc. AE: Cerebellar disorder NOS, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 66.7%)
Diarrhea (grade 3, 66.7%)
Sources: Page: p.363, 366
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 33.3%)
Cerebellar disorder NOS (grade 5, 16.7%)
Sources: Page: p.2578
3 g/m2 2 times / day multiple, intravenous
MTD
Dose: 3 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 3 g/m2, 2 times / day
Sources: Page: p.366
unhealthy, 16-76
n = 27
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 27
Sources: Page: p.366
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Disc. AE: Bone marrow depression, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Leukopenia
Thrombocytopenia
Anemia
Nausea
Vomiting
Diarrhea
Abdominal pain
Oral ulceration
Hepatic dysfunction NOS
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 3, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Cerebellar disorder NOS grade 4, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Cerebellar disorder NOS grade 4, 33.3%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Cerebellar disorder NOS grade 5, 16.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Abdominal pain Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Anemia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Bone marrow depression Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Diarrhea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Hepatic dysfunction NOS Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Leukopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Nausea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Oral ulceration Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Thrombocytopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Vomiting Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 6.6 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
2000 Jul
Visual loss following high-dose cytosine arabinoside (ARA-C).
2000 Mar
Misdiagnosis of broad-complex tachycardia.
2000 Nov-Dec
Heterotopia in microcephaly induced by cytosine arabinoside: hippocampus in the neocortex.
2000 Oct
Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity.
2000 Sep
Treatment for primary CNS lymphoma: the next step.
2000 Sep
Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.
2001 Apr
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
2001 Apr
The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway.
2001 Apr 1
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
2001 Apr 1
Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells.
2001 Apr 15
Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.
2001 Apr-May
[Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C].
2001 Feb
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
2001 Feb
Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
2001 Feb
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
2001 Feb
Bilateral breast relapse in acute myelogenous leukemia.
2001 Feb
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.
2001 Feb
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
2001 Feb
Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia.
2001 Feb
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
2001 Feb 15
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
2001 Feb 15
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
2001 Feb 16
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP.
2001 Feb 2
Characterization of DNA fragmentation events caused by genotoxic and non-genotoxic agents.
2001 Feb 20
[Palpable mantel cell lymphoma in the breast].
2001 Feb 3
Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation.
2001 Jan
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
2001 Jan
Aseptic meningitis in a child after systemic treatment with high dose cytarabine.
2001 Jan
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
2001 Jan
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
2001 Jan
Acute progranulocytic leukemia.
2001 Jan
Chemotherapy and marrow transplantation for congenital leukaemia.
2001 Jan
Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
2001 Jan 1
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment.
2001 Jan 1
Porcine Choroid plexus epithelial cells in culture: regulation of barrier properties and transport processes.
2001 Jan 1
Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes.
2001 Jan 15
JP-8 jet fuel-induced DNA damage in H4IIE rat hepatoma cells.
2001 Jan 25
Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons.
2001 Jan 31
The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.
2001 Jan-Feb
Therapy of acute myeloid leukemia.
2001 Jan-Feb
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
2001 Mar
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.
2001 Mar
Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
2001 Mar
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
2001 Mar
Severe hepatic injury associated with lipid formulations of amphotericin B.
2001 Mar 1
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
2001 Mar 15
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
2001 Mar 15
Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
2001 Mar 2
Patents

Sample Use Guides

Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3). Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).
Route of Administration: Intratracheal
In Vitro Use Guide
Curator's Comment:: The effect of Ara-C (0.1 μM) treatment on HUVEC proliferation alone or in drug combinations compared to drug-free control cultures. Results are expressed as mean percentage ± SEM from three independent experiments (six replicates per condition) relative to corresponding untreated control cultures.
Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:58:26 UTC 2021
Edited
by admin
on Fri Jun 25 20:58:26 UTC 2021
Record UNII
04079A1RDZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTARABINE
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CYTARABINE [USP-RS]
Common Name English
CYTARABINE [HSDB]
Common Name English
CYTOSAR-U
Brand Name English
CYTARABINE [EP MONOGRAPH]
Common Name English
CYTARABINE [WHO-IP]
Common Name English
CYTARABINUM [WHO-IP LATIN]
Common Name English
DEPOCYT
Brand Name English
ARACYTIN
Common Name English
U-19,920
Code English
CYTARABINE [USAN]
Common Name English
CYTARABINE LIPOSOME
VANDF  
Common Name English
CYTARABINE [VANDF]
Common Name English
ARACYTIDINE
Common Name English
SPONGOCYTIDINE
Common Name English
CYTARABINE [MI]
Common Name English
ARABINOCYTOSINE
Common Name English
CYTARABINE [ORANGE BOOK]
Common Name English
CYTARABINE [USP]
Common Name English
ARA-C
Common Name English
CYTARABINE LIPOSOME [VANDF]
Common Name English
1-.BETA.-D-ARABINOFURANOSYLCYTOSINE
Common Name English
VYXEOS COMPONENT CYTARABINE
Brand Name English
NSC-287459
Code English
U 19920A
Common Name English
CYTARABINE [MART.]
Common Name English
CYTARABINOSIDE
Common Name English
CYTARABINE [JAN]
Common Name English
U-19920
Code English
ARACYTINE
Common Name English
CYTARABINE [INN]
Common Name English
CYTARABINE [EMA EPAR]
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-
Common Name English
CYTARABINE [WHO-DD]
Common Name English
CYTARABINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC L01XY01
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
FDA ORPHAN DRUG 234806
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
NDF-RT N0000175595
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
NDF-RT N0000000233
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
EMA ASSESSMENT REPORTS DEPOCYT (AUTHORIZED: MENINGEAL NEOPLASMS)
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
FDA ORPHAN DRUG 265808
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
NCI_THESAURUS C1557
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
FDA ORPHAN DRUG 73393
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
LIVERTOX 254
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
WHO-ATC L01BC01
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
EU-Orphan Drug EU/3/11/942
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
WHO-VATC QL01BC01
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
Code System Code Type Description
RXCUI
968804
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
ALTERNATIVE
ECHA (EC/EINECS)
205-705-9
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
EPA CompTox
147-94-4
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
DRUG BANK
DB00987
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
EVMPD
SUB06880MIG
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
NCI_THESAURUS
C408
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
RXCUI
3041
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
MERCK INDEX
M4051
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY Merck Index
PUBCHEM
6253
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
WIKIPEDIA
CYTARABINE
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
USP_CATALOG
1162002
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY USP-RS
ChEMBL
CHEMBL803
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
FDA UNII
04079A1RDZ
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
IUPHAR
4827
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
DRUG CENTRAL
770
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
CAS
147-94-4
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
MESH
D003561
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
INN
1709
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
HSDB
3049
Created by admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
kcat
METABOLIC ENZYME -> SUBSTRATE
Km
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE INACTIVE -> PARENT
Produced via Cytidine deaminase exposure.
PLASMA
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC